| Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis SA Buckley, BL Wood, M Othus, CS Hourigan, C Ustun, MA Linden, ... haematologica 102 (5), 865, 2017 | 255 | 2017 |
| Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study … B Sarina, L Castagna, L Farina, F Patriarca, F Benedetti, AM Carella, ... Blood, The Journal of the American Society of Hematology 115 (18), 3671-3677, 2010 | 196 | 2010 |
| Real-time quantitation of minimal residual disease in inv (16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state S Buonamici, E Ottaviani, N Testoni, V Montefusco, G Visani, F Bonifazi, ... Blood, The Journal of the American Society of Hematology 99 (2), 443-449, 2002 | 177 | 2002 |
| The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia–analysis of 848 patients G Visani, P Bernasconi, M Boni, GL Castoldi, S Ciolli, M Clavio, MC Cox, ... Leukemia 15 (6), 903-909, 2001 | 112 | 2001 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 101 | 2015 |
| Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria C Cattaneo, R Di Blasi, C Skert, A Candoni, B Martino, N Di Renzo, ... Annals of hematology 97, 1717-1726, 2018 | 95 | 2018 |
| Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study PP Piccaluga, G Visani, SA Pileri, S Ascani, T Grafone, A Isidori, ... Leukemia 16 (9), 1609-1614, 2002 | 91 | 2002 |
| Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1–risk myelodysplastic syndromes C Filì, M Malagola, MY Follo, C Finelli, I Iacobucci, G Martinelli, F Cattina, ... Clinical Cancer Research 19 (12), 3297-3308, 2013 | 88 | 2013 |
| Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas PP Piccaluga, G Martinelli, M Rondoni, M Malagola, S Gaitani, A Isidori, ... Leukemia & lymphoma 45 (9), 1791-1795, 2004 | 84 | 2004 |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 81 | 2019 |
| Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation S Bernardi, M Malagola, C Zanaglio, N Polverelli, E Dereli Eke, M D’Adda, ... Cancer medicine 8 (5), 2041-2055, 2019 | 80 | 2019 |
| Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study C Skert, D Damiani, A Michelutti, F Patriarca, M Arpinati, C Fili, P Lucchi, ... Bone marrow transplantation 44 (11), 729-737, 2009 | 67 | 2009 |
| Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia D Russo, G Martinelli, M Malagola, C Skert, S Soverini, I Iacobucci, ... Blood, The Journal of the American Society of Hematology 121 (26), 5138-5144, 2013 | 61 | 2013 |
| Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts G Martinelli, E Ottaviani, S Buonamici, A Isidori, G Borsaru, G Visani, ... Haematologica 88 (11), 1221-1228, 2003 | 60 | 2003 |
| Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives M Malagola, C Papayannidis, M Baccarani Annals of hematology 95, 681-693, 2016 | 54 | 2016 |
| First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients PP Piccaluga, G Martinelli, M Rondoni, M Malagola, S Gaitani, G Visani, ... Leukemia research 28 (9), 987-990, 2004 | 50 | 2004 |
| Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo … M Malagola, V Cancelli, C Skert, PF Leali, E Ferrari, A Tiburzi, ML Sala, ... Transplantation 100 (12), e147-e155, 2016 | 49 | 2016 |
| Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin versus idarubicin, Ara‐C and etoposide for induction treatment of younger, newly … D Russo, M Malagola, A de Vivo, M Fiacchini, G Martinelli, PP Piccaluga, ... British journal of haematology 131 (2), 172-179, 2005 | 49 | 2005 |
| Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia G Visani, D Milligan, F Leoni, J Chang, S Kelsey, R Marcus, R Powles, ... Leukemia 15 (5), 764-771, 2001 | 47 | 2001 |
| Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia G Visani, G Rosti, G Bandini, P Tosi, A Isidori, M Malagola, M Stanzani, ... British journal of haematology 109 (4), 722-728, 2000 | 46 | 2000 |
